Floatz logo

Hynr-Cs-Allo

Central Nervous System Disease

Hanyang University Seoul HospitalCell therapyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Central Nervous System Disease cohort.

Asset / SponsorPhaseRating
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
ENCENICLINE
FORUM Pharmaceuticals Inc
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

Hynr-Cs-Allo is also rated in:

neuromuscular diseaseDormant
CC
Indicative ·
47 / 100
View asset →
neurodegeneration with brain iron accumulationDormant
CC
Indicative ·
47 / 100
View asset →
Motor Neuron DiseaseDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →